Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

CCOHTA’s drug treatment review for MS

high cost/QALY

    • 6 Accesses

    This is a preview of subscription content, log in to check access.

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    CCOHTA’s drug treatment review for MS. Pharmacoecon. Outcomes News 201, 8 (1999). https://doi.org/10.1007/BF03280141

    Download citation

    Keywords

    • Multiple Sclerosis
    • Interferon
    • Adis International Limited
    • Acute Exacerbation
    • Health Technology Assessment